Therapeutics News

The FDA has released a new application for investigative drugs that it says will cut the amount of time physicians spend filling out such requests, as part of a larger effort to “streamline” the process of providing medications still undergoing regulatory review to their patients with severe illness.

Investigators from Imprimis Pharmaceuticals announced positive clinical study results with its triamcinolone acetonide, moxifloxacin HCl and vancomycin Dropless Therapy formation in patients after cataract surgery at the American Society of Cataract and Refractive Surgery Congress.

Ocular surface diseases, such as dry eye disease, can be caused by a number of triggers, including glaucoma treatment, allergies, computer use, the environment, the natural aging process or a combination of factors. By treating ocular surface disease in patients with glaucoma or other eye disease, we can improve patient satisfaction and compliance.

SEATTLE – A retrospective analysis has found that 3 months after laser trabeculoplasty, 60% of open-angle glaucoma patients were prescribed at least one topical glaucoma medication.

SEATTLE – Preliminary 2015 data from the Antibiotic Resistance Monitoring in Ocular Microorganism study show that high levels of antibiotic resistance continue among Staphylococcus, especially the methicillin-resistant strains, according to a poster presented here at the Association of Research in Vision and Ophthalmology meeting.

SEATTLE – Saline containing 0.01% pure hypochlorous acid was found to reduce Staphylococcus overall from the skin below the eyelid in 99.6% of ocular specimens, according to David W. Stroman, PhD.

Researchers found that twice-daily ocular doses of trabodenoson were well tolerated and decreased IOP in patients with ocular hypertension or primary open-angle glaucoma.

Low-dose topical tacrolimus 0.01% solution showed long-term, positive results as a steroid-sparing agent in the management of refractory vernal keratoconjunctivitis, according to researchers in Clinical Ophthalmology.

“Why do they call it Muro-128?” This one stumped me.

NEW YORK – A trio of clinicians recommended the use of punctal occlusion, with specific caveats depending on preoperative use and the type of ocular surface disease the patient is experiencing.